NI201100134A - Compuestos de quinazolina sustituidos. - Google Patents

Compuestos de quinazolina sustituidos.

Info

Publication number
NI201100134A
NI201100134A NI201100134A NI201100134A NI201100134A NI 201100134 A NI201100134 A NI 201100134A NI 201100134 A NI201100134 A NI 201100134A NI 201100134 A NI201100134 A NI 201100134A NI 201100134 A NI201100134 A NI 201100134A
Authority
NI
Nicaragua
Prior art keywords
methods
kinase
ameliorating
treating
diseases
Prior art date
Application number
NI201100134A
Other languages
English (en)
Inventor
Leriche Caroline
Auclair Eric
Le Roux Jacques
Middlemiss David
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41735344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201100134(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of NI201100134A publication Critical patent/NI201100134A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se dirige a ciertos compuestos novedosos, métodos para producirlos y métodos para tratar o mejorar un trastorno mediado por cinasa. Más particularmente, esta invención se dirige un compuestos de quinazolina sustituidos útiles como inhibidores de cinasa selectivos, métodos para producir tales compuestos y métodos para tratar o mejorar un trastorno mediado por cinasa, En particular, los métodos se relacionan con el tratamiento o mejora de un trastorno mediado por cinasa que incluye enfermedades cardiovasculares, diabetes, trastornos asociados con diabetes, enfermedades inflamatorias, trastornos inmunológicos, cáncer y enfermedades de los ojos tales como retinopatías o degeneración macular u otras enfermedades vitreorretinianas, y similares.
NI201100134A 2008-12-29 2011-06-29 Compuestos de quinazolina sustituidos. NI201100134A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08360043 2008-12-29

Publications (1)

Publication Number Publication Date
NI201100134A true NI201100134A (es) 2012-03-06

Family

ID=41735344

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201100134A NI201100134A (es) 2008-12-29 2011-06-29 Compuestos de quinazolina sustituidos.

Country Status (23)

Country Link
US (1) US8389530B2 (es)
EP (1) EP2381943A1 (es)
JP (1) JP2012514020A (es)
KR (1) KR20110120878A (es)
CN (1) CN102333533A (es)
AU (1) AU2009334869A1 (es)
BR (1) BRPI0924067A2 (es)
CA (1) CA2748319A1 (es)
CO (1) CO6390105A2 (es)
CR (1) CR20110368A (es)
DO (1) DOP2011000209A (es)
EA (1) EA019110B1 (es)
EC (1) ECSP11011204A (es)
IL (1) IL213742A0 (es)
MA (1) MA32968B1 (es)
MX (1) MX2011007064A (es)
NI (1) NI201100134A (es)
NZ (1) NZ593949A (es)
PE (1) PE20120424A1 (es)
SG (1) SG172415A1 (es)
TN (1) TN2011000319A1 (es)
WO (1) WO2010076238A1 (es)
ZA (1) ZA201104777B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081960A1 (es) 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
SG11201500125QA (en) 2012-07-11 2015-02-27 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
WO2015061572A1 (en) 2013-10-25 2015-04-30 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
KR101715448B1 (ko) * 2014-07-16 2017-03-20 주식회사 큐리언트 염증성 질환 치료용 화합물
CN107428693B (zh) 2014-12-24 2020-05-29 吉利德科学公司 用于hiv治疗的异喹啉化合物
MX2017008520A (es) 2014-12-24 2018-03-01 Gilead Sciences Inc Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
CN112239459B (zh) * 2019-07-19 2021-11-26 中国科学院上海药物研究所 稠环嘧啶氨基化合物、其制备方法、药物组合物及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2386955A1 (en) * 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
BRPI0406809A (pt) 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
CA2542329A1 (en) 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
RU2006139258A (ru) 2004-04-08 2008-05-20 Таргеджен, Инк. (US) Бензотриазиновые ингибиторы киназ
AU2005276974B2 (en) 2004-08-25 2012-08-02 Targegen, Inc. Heterocyclic compounds and methods of use
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CN101155799A (zh) 2005-03-16 2008-04-02 塔格根公司 嘧啶化合物和使用方法
EP1878727A4 (en) * 2005-04-28 2013-11-13 Kyowa Hakko Kirin Co Ltd 2-AMINOQUINAZOLINE DERIVATIVES
US20060292203A1 (en) 2005-06-08 2006-12-28 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
AU2007336893A1 (en) * 2006-12-22 2008-07-03 Novartis Ag Quinazolines for PDK1 inhibition

Also Published As

Publication number Publication date
CN102333533A (zh) 2012-01-25
BRPI0924067A2 (pt) 2016-01-26
NZ593949A (en) 2013-08-30
CO6390105A2 (es) 2012-02-29
IL213742A0 (en) 2011-07-31
US20120004210A1 (en) 2012-01-05
MX2011007064A (es) 2012-01-20
KR20110120878A (ko) 2011-11-04
ECSP11011204A (es) 2011-10-31
ZA201104777B (en) 2012-03-28
AU2009334869A2 (en) 2011-09-29
EP2381943A1 (en) 2011-11-02
WO2010076238A1 (en) 2010-07-08
TN2011000319A1 (en) 2012-12-17
CR20110368A (es) 2011-12-02
DOP2011000209A (es) 2011-09-30
EA019110B1 (ru) 2014-01-30
CA2748319A1 (en) 2010-07-08
US8389530B2 (en) 2013-03-05
EA201101012A1 (ru) 2012-01-30
MA32968B1 (fr) 2012-01-02
JP2012514020A (ja) 2012-06-21
PE20120424A1 (es) 2012-05-04
SG172415A1 (en) 2011-07-28
AU2009334869A1 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
NI201100134A (es) Compuestos de quinazolina sustituidos.
CO6420343A2 (es) [1, 2, 4] triazolo [1, 5 -a] piridinas como inhibidores de cinasa
CR20140397A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
CO6660505A2 (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
CR20110103A (es) Heteroarilos sustituidos
CU20130115A7 (es) Compuestos y composiciones como inhibidores de trk
WO2012125408A8 (en) Pegylated apelin and uses thereof
CR20140107A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
BR112012028136A2 (pt) terapia de combinaçao
CO6551721A2 (es) Moduladores de cinasa novedosos
CO6341558A2 (es) Antagonistas del recepptor de nmda para el tratamiento de trastornos neuropsiquiatricos
MX342329B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
NI201000214A (es) Moduladores de diamino-piridina, pirimidina, y piridazina del receptor de la histamina h4.
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
ECSP15025093A (es) Derivados de Oxazolidin-2-ona-Pirimidina
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
CL2011001845A1 (es) Uso de un agente terapeutico en el talamo mediante distribucion por conveccion mejorada (ced) para tratar un trastorno neurologico cortical.
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
TR201909158T4 (tr) siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları.
MX340536B (es) Terapia direccionada al receptor del factor de crecimiento epidermico (egfr).
BR112015007095A2 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados
SV2010003658A (es) Uso de un compuesto para el tratamiento de trastornos relacionados con los ojos
ECSP15011105A (es) siRNA Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE TRASTORNOS OCULARES